LAUSR

Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant drug. This drug is not official in any pharmacopeia. The objective of this study was to develop, validate, and compare spectrophotometric [absorptivity value method, derivative spectroscopy method, and area under curve (AUC) method] and high-performance liquid chromatography (HPLC) methods for the determination of deflazacort in the pharmaceutical dosage form (tablets). The Method A is simple absorptivity value method and is established on the determination of deflazacort in ethanol and water at 247 nm. The Method B is a derivative spectrophotometric method and engrosses the measurement of deflazacort using the zero-orderand first-order derivative technique at 276.5 nm as maxima and 228.2 nm as minima. Method C is an AUC method. This method entails the computation of the incorporated value of absorbance with context to the wavelength between two selected wavelengths 230.2 and 264.4 nm, respectively. Method D is by HPLC, which was carried out using C18 column, mobile phase consisting of acetonitrile:methanol:phosphate buffer pH 7.0 (90:5:5 v/v/v) with flow rate 1 ml/minute and detection done at 247 nm, which provide a sharp peak with a short retention time of 4.025 minutes. The advantage of this HPLC method can be observed from its attributes, such as asymmetry (1.1732), column efficiency (718610.6), and standard deviation (0.5929868), which indicated that the developed system has better eluting characteristics than the previously developed method. However, the limit of detection is marginally lower than that of the previous method. Since, the method is not available in any pharmacopeia for the routine analysis of deflazacort, the novel developed spectroscopic and RP-HPLC methods may be highly useful for the industries manufacturing and maintaining the quality aspects of this drug.